Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

Maria H. Sjogren; Robert Sjogren; Michael F. Lyons; Michael Ryan; John Santoro; Coleman Smith; K. Rajender Reddy; Herbert Bonkovsky; Brooke Huntley; Sima Faris-Young

doi:10.1007/s10620-007-9757-9

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

Maria H. Sjogren^*, Robert Sjogren, Michael F. Lyons, Michael Ryan, John Santoro, Coleman Smith, K. Rajender Reddy, Herbert Bonkovsky, Brooke Huntley, Sima Faris-Young

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.

Original language	English
Pages (from-to)	1540-1547
Number of pages	8
Journal	Digestive Diseases and Sciences
Volume	52
Issue number	6
DOIs	https://doi.org/10.1007/s10620-007-9757-9
State	Published - Jun 2007
Externally published	Yes

Keywords

African-American
Depression
Interferon alfacon-1
Quality of life
Viral hepatitis
Viral load

Access to Document

10.1007/s10620-007-9757-9

Cite this

@article{a6c105c6f24146eabd46e5c2f9cdfb50,

title = "Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin",

abstract = "Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.",

keywords = "African-American, Depression, Interferon alfacon-1, Quality of life, Viral hepatitis, Viral load",

author = "Sjogren, {Maria H.} and Robert Sjogren and Lyons, {Michael F.} and Michael Ryan and John Santoro and Coleman Smith and Reddy, {K. Rajender} and Herbert Bonkovsky and Brooke Huntley and Sima Faris-Young",

year = "2007",

month = jun,

doi = "10.1007/s10620-007-9757-9",

language = "English",

volume = "52",

pages = "1540--1547",

journal = "Digestive Diseases and Sciences",

issn = "0163-2116",

number = "6",

}

TY - JOUR

T1 - Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

AU - Sjogren, Maria H.

AU - Sjogren, Robert

AU - Lyons, Michael F.

AU - Ryan, Michael

AU - Santoro, John

AU - Smith, Coleman

AU - Reddy, K. Rajender

AU - Bonkovsky, Herbert

AU - Huntley, Brooke

AU - Faris-Young, Sima

PY - 2007/6

Y1 - 2007/6

N2 - Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.

AB - Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.

KW - African-American

KW - Depression

KW - Interferon alfacon-1

KW - Quality of life

KW - Viral hepatitis

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=34248661259&partnerID=8YFLogxK

U2 - 10.1007/s10620-007-9757-9

DO - 10.1007/s10620-007-9757-9

M3 - Article

C2 - 17406822

AN - SCOPUS:34248661259

SN - 0163-2116

VL - 52

SP - 1540

EP - 1547

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

IS - 6

ER -

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

Abstract

Keywords

Access to Document

Fingerprint

Cite this